84 related articles for article (PubMed ID: 33906100)
41. Social disparities in access to breast and cervical cancer screening by women living in Spain.
Ricardo-Rodrigues I; Jiménez-García R; Hernández-Barrera V; Carrasco-Garrido P; Jiménez-Trujillo I; López de Andrés A
Public Health; 2015 Jul; 129(7):881-8. PubMed ID: 25818014
[TBL] [Abstract][Full Text] [Related]
42. Cervical cancer screening outcomes in Zambia, 2010-19: a cohort study.
Pry JM; Manasyan A; Kapambwe S; Taghavi K; Duran-Frigola M; Mwanahamuntu M; Sikazwe I; Matambo J; Mubita J; Lishimpi K; Malama K; Bolton Moore C
Lancet Glob Health; 2021 Jun; 9(6):e832-e840. PubMed ID: 34019837
[TBL] [Abstract][Full Text] [Related]
43. Participation in interventions and recommended follow-up for non-attendees in cervical cancer screening -taking the women's own preferred test method into account-A Swedish randomised controlled trial.
Lilliecreutz C; Karlsson H; Spetz Holm AC
PLoS One; 2020; 15(7):e0235202. PubMed ID: 32614875
[TBL] [Abstract][Full Text] [Related]
44. Organized primary human papillomavirus-based cervical screening: A randomized healthcare policy trial.
Elfström KM; Eklund C; Lamin H; Öhman D; Hortlund M; Elfgren K; Sundström K; Dillner J
PLoS Med; 2021 Aug; 18(8):e1003748. PubMed ID: 34424907
[TBL] [Abstract][Full Text] [Related]
45. Cervical cancer screening in the United States, 1993-2010: characteristics of women who are never screened.
Chen HY; Kessler CL; Mori N; Chauhan SP
J Womens Health (Larchmt); 2012 Nov; 21(11):1132-8. PubMed ID: 22873781
[TBL] [Abstract][Full Text] [Related]
46. Prevalence and Predictor of Cervical Cancer Screening Service Uptake Among Women Aged 25 Years and Above in Sidama Zone, Southern Ethiopia, Using Health Belief Model.
Gemeda EY; Kare BB; Negera DG; Bona LG; Derese BD; Akale NB; Kebede KM; Koboto DD; Tekle AG
Cancer Control; 2020; 27(1):1073274820954460. PubMed ID: 32951445
[TBL] [Abstract][Full Text] [Related]
47. High-grade cervical abnormalities and screening intervals in New South Wales, Australia.
Schindeler S; Morrell S; Zuo Y; Baker D
J Med Screen; 2008; 15(1):36-43. PubMed ID: 18416954
[TBL] [Abstract][Full Text] [Related]
48. Cervical cancer in women with comprehensive health care access: attributable factors in the screening process.
Leyden WA; Manos MM; Geiger AM; Weinmann S; Mouchawar J; Bischoff K; Yood MU; Gilbert J; Taplin SH
J Natl Cancer Inst; 2005 May; 97(9):675-83. PubMed ID: 15870438
[TBL] [Abstract][Full Text] [Related]
49. Analysis of the effects of the age-period-birth cohort on cervical cancer mortality in the Brazilian Northeast.
Meira KC; Silva GWDS; Dos Santos J; Guimarães RM; de Souza DLB; Ribeiro GPC; Dantas ESO; Carvalho JBL; Jomar RT; Simões TC
PLoS One; 2020; 15(2):e0226258. PubMed ID: 32074101
[TBL] [Abstract][Full Text] [Related]
50. Temporal Patterns of Cervical Cancer Screening Among Danish Women 55 Years and Older Diagnosed With Cervical Cancer.
Hammer A; Hee L; Blaakær J; Gravitt P
J Low Genit Tract Dis; 2018 Jan; 22(1):1-7. PubMed ID: 29271849
[TBL] [Abstract][Full Text] [Related]
51. Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from China.
Zhao FH; Lin MJ; Chen F; Hu SY; Zhang R; Belinson JL; Sellors JW; Franceschi S; Qiao YL; Castle PE;
Lancet Oncol; 2010 Dec; 11(12):1160-71. PubMed ID: 21075054
[TBL] [Abstract][Full Text] [Related]
52. Most women diagnosed with cervical cancer by a visual screening program in Tanzania completed treatment: evidence from a retrospective cohort study.
Gard AC; Soliman AS; Ngoma T; Mwaiselage J; Kahesa C; Chamberlain RM; Harlow SD
BMC Public Health; 2014 Sep; 14():910. PubMed ID: 25187329
[TBL] [Abstract][Full Text] [Related]
53. The impact on women's health and the cervical cancer screening budget of primary HPV screening with dual-stain cytology triage in Belgium.
Tjalma WAA; Kim E; Vandeweyer K
Eur J Obstet Gynecol Reprod Biol; 2017 May; 212():171-181. PubMed ID: 28081908
[TBL] [Abstract][Full Text] [Related]
54. Follow-up and timeliness after an abnormal cancer screening among underserved, urban women in a patient navigation program.
Markossian TW; Darnell JS; Calhoun EA
Cancer Epidemiol Biomarkers Prev; 2012 Oct; 21(10):1691-700. PubMed ID: 23045544
[TBL] [Abstract][Full Text] [Related]
55. Delays in treatment initiation and conclusion in women with stage IA to IIIB cervical cancer: A survival study in a hospital-based cohort from a developing country.
da Silva IF; da Silva IF; Saraceni V; Koifman RJ
Cancer Epidemiol; 2023 Oct; 86():102450. PubMed ID: 37678095
[TBL] [Abstract][Full Text] [Related]
56. Cervical cancer specific survival in Grande Cuiabá, Mato Grosso State, Brazil.
Lima FCDS; Souza BDSN; Oliveira JFP; Galvão ND; Souza PCF
Rev Bras Epidemiol; 2022; 25(Supl 1):e220017. PubMed ID: 35766774
[TBL] [Abstract][Full Text] [Related]
57. Social determinants influencing cervical cancer diagnosis: an ecological study.
Galindo JF; Formigari GM; Zeferino LC; Carvalho CF; Ursini EL; Vale DB
Int J Equity Health; 2023 May; 22(1):102. PubMed ID: 37231421
[TBL] [Abstract][Full Text] [Related]
58. Impact of the delay to start treatment in patients with lung cancer treated in a densely populated area of Brazil.
Abrao FC; Abreu IRLB; Rocha RO; Munhoz FD; Rodrigues JHG; Younes RN
Clinics (Sao Paulo); 2017 Nov; 72(11):675-680. PubMed ID: 29236913
[TBL] [Abstract][Full Text] [Related]
59. Overall survival analyses of female malignancies in Southern Brazil during 2008-2017: A closer look at breast, cervical and ovarian cancer.
Schneider IJC; Schmidt TP; Dos Santos AMM; Correa VP; Garcia LP; de Oliveira C; Franzoi MA
Dialogues Health; 2022 Dec; 1():100010. PubMed ID: 38515875
[TBL] [Abstract][Full Text] [Related]
60. Deterministic linkage for improving follow-up time in a Brazilian population-based cancer registry.
Pereira TF; Aranha VJ; Waldvogel BC; da Costa AM; Tavares Guerreiro Fregnani JH
Sci Rep; 2023 Mar; 13(1):4816. PubMed ID: 36964184
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
